학술논문

Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine.
Document Type
Article
Source
Science Translational Medicine; 6/15/2022, Vol. 14 Issue 649, p1-17, 17p
Subject
PEPTIDES
T cell receptors
CANCER vaccines
MYELOPROLIFERATIVE neoplasms
CALRETICULIN
T cells
MAJOR histocompatibility complex
Language
ISSN
19466234
Abstract
Copyright of Science Translational Medicine is the property of American Association for the Advancement of Science and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)